HanssenMJHoeksJBransBVan Der LansAASchaartGVan Den DriesscheJJet al
Prime Therapeutics leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years 3 Article Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
* Will affordability unlock a much larger patient population in India
We were finding ourselves going in and out of hospitals, sitting down with our notebooks taking copious notes and taking videos of everything someone was doing with the insulin jar." Now, she's advocating for awareness of screening for type 1 diabetes in kids
I ordered GLP-1s from Belle, reviewed the service firsthand, and scored it using our carefully crafted review methodology
So if a patient is seeing someone with experience treating obesity, then they usually will be able to find a cost-effective treatment